Circulating Endothelial Progenitor Cells and Aortic Aneurysm

• Conditions: - Aortic Aneurysm

• Registration Number: NCT01918982
• Lead Sponsor: Hopital Jean Minjoz

Brief Summary

We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Detailed Description

Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level. 40 patients followed for known aortic aneurysm \>30mm and \<50mm will be followed up every 6 months during 2 years. Each 6 months they will have a consultation by their physiologist with an echo or a CT-scan. At the same time, a 10ML blood sample will be taken to assess the circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Study Timeline

• Status Verified: 2013-08
• Study First Submitted: 2013-08-06
• Study First Submitted QC: 2013-08-07
• Last Update Submitted: 2013-08-07
• Study First Posted: 2013-08-08
• Last Update Posted: 2013-08-08
• Study Start: 2013-10
• Primary Completion: 2016-02
• Study Completion: 2016-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Aortic aneurysm size >30mm and > 50mm

Exclusion Criteria

• Infectious disease
• Inflammatory disease
• Liver insuffisency
• Cancer evolutive
• Pregnant women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood concentration	2 years	Patients are followed for 2 years